BNT162b2-vaccine-induced neutralization responses are immune correlates of clinical protection against SARS-CoV-2 in heart transplant recipients.
BNT162b2 vaccine
SARS-CoV-2
correlates
heart transplantation
neutralization
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
18
07
2023
received:
22
06
2023
accepted:
25
07
2023
medline:
13
11
2023
pubmed:
13
8
2023
entrez:
12
8
2023
Statut:
ppublish
Résumé
Defining immune correlates of protection against COVID-19 is pivotal for optimizing the use of COVID-19 vaccines, predicting the impact of novel variants on clinical outcomes, and advancing the development of immunotherapies and next-generation vaccines. We aimed to identify vaccine-induced immune correlates of protection against COVID-19-related hospitalizations in a highly vaccinated heart transplant (HT) cohort. In a case-control study of HT recipients vaccinated with the BNT162b2 vaccine, patients were prospectively assessed for vaccine-induced neutralization of the wild-type virus, and the Delta and Omicron BA.1, BA.2, BA.4, and BA.5 variants. Comparative analyses with controls were conducted to identify correlates of protection against COVID-19 hospitalization. ROC analyses were performed. Primary outcomes were COVID-19 hospitalizations and severity of SARS-CoV-2 breakthrough infection. The study cohort comprised 59 HT recipients aged 58 (49,65) years with breakthrough infections after three or four monovalent BNT162b2 doses; 41 (69.5%) were men. Thirty-six (61%) patients with COVID-19 were hospitalized; most cases were non-severe (58, 98%). For hospitalized (vs. non-hospitalized) COVID-19 patients, vaccine-induced neutralization titers were significantly lower against all SARS-CoV-2 variants (p < .005). Vaccine-induced neutralization of the wild-type virus and delta and omicron BA.1, BA.2, BA.4, and BA.5 variants was associated with a reduced risk for COVID-19-related hospitalization. The optimal neutralization titer thresholds that were predictive of COVID-19 hospitalizations were 96 (wild-type), 48 (delta), 12 (BA.1), 96 (BA.2), 96 (BA.4), and 48 (BA.5). BNT162b2-vaccine-induced neutralization responses are immune correlates of protection and confer clinical protection against COVID-19 hospitalizations.
Sections du résumé
BACKGROUND
Defining immune correlates of protection against COVID-19 is pivotal for optimizing the use of COVID-19 vaccines, predicting the impact of novel variants on clinical outcomes, and advancing the development of immunotherapies and next-generation vaccines. We aimed to identify vaccine-induced immune correlates of protection against COVID-19-related hospitalizations in a highly vaccinated heart transplant (HT) cohort.
METHODS
In a case-control study of HT recipients vaccinated with the BNT162b2 vaccine, patients were prospectively assessed for vaccine-induced neutralization of the wild-type virus, and the Delta and Omicron BA.1, BA.2, BA.4, and BA.5 variants. Comparative analyses with controls were conducted to identify correlates of protection against COVID-19 hospitalization. ROC analyses were performed. Primary outcomes were COVID-19 hospitalizations and severity of SARS-CoV-2 breakthrough infection.
RESULTS
The study cohort comprised 59 HT recipients aged 58 (49,65) years with breakthrough infections after three or four monovalent BNT162b2 doses; 41 (69.5%) were men. Thirty-six (61%) patients with COVID-19 were hospitalized; most cases were non-severe (58, 98%). For hospitalized (vs. non-hospitalized) COVID-19 patients, vaccine-induced neutralization titers were significantly lower against all SARS-CoV-2 variants (p < .005). Vaccine-induced neutralization of the wild-type virus and delta and omicron BA.1, BA.2, BA.4, and BA.5 variants was associated with a reduced risk for COVID-19-related hospitalization. The optimal neutralization titer thresholds that were predictive of COVID-19 hospitalizations were 96 (wild-type), 48 (delta), 12 (BA.1), 96 (BA.2), 96 (BA.4), and 48 (BA.5).
CONCLUSIONS
BNT162b2-vaccine-induced neutralization responses are immune correlates of protection and confer clinical protection against COVID-19 hospitalizations.
Substances chimiques
Antibodies, Viral
0
BNT162 Vaccine
0
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15091Informations de copyright
© 2023 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd.
Références
Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399(10326):757-768. doi:10.1016/S0140-6736(21)02346-1
Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol. 2017;25(1):35-48. doi:10.1016/j.tim.2016.09.001
Ison MG, Hirsch HH. Community-acquired respiratory viruses in transplant patients: diversity, impact, unmet clinical needs. Clin Microbiol Rev. 2019;32(4):e00042-19. doi:10.1128/CMR.00042-19
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17-41. doi:10.1002/JLB.3COVR0520-272R
Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75(10):2445-2476. doi:10.1111/all.14462
Hu W, Yen YT, Singh S, Kao CL, Wu-Hsieh BA. SARS-CoV regulates immune function-related gene expression in human monocytic cells. Viral Immunol. 2012;25(4):277-288. doi:10.1089/vim.2011.0099
Aslam S, Ison MG. SARS-CoV-2 vaccination in heart transplantation: what we do and do not know. J Heart Lung Transplant. 2022;41(2):158-160. doi:10.1016/j.healun.2021.10.017
Hazan F, Verdonk C, Coutance G, et al. Severity of SARS-CoV-2 omicron variant infection in heart transplant recipients. J Heart Lung Transplant. 2023;42(5):558-561. doi:10.1016/j.healun.2023.01.012
Peled Y, Ram E, Lavee J, et al. BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. J Heart Lung Transplant. 2021;40(8):759-762. doi:10.1016/j.healun.2021.04.003
Peled Y, Ram E, Lavee J, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2022;41(2):148-157. doi:10.1016/j.healun.2021.08.010
Peled Y, Afek A, Kreiss Y, et al. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant. J Heart Lung Transplant. 2022;41(10):1417-1425. doi:10.1016/j.healun.2022.05.014
Peled Y, Afek A, Nemet I, et al. Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation. J Heart Lung Transplant. 2022;41(9):1210-1213. doi:10.1016/j.healun.2022.04.014
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
Polack FP, Thomas SJ, Kitchin N, et al, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
Muhsen K, Maimon N, Mizrahi AY, et al. Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities. JAMA Intern Med. 2022;182(8):859-867. doi:10.1001/jamainternmed.2022.2658
Amanatidou E, Gkiouliava A, Pella E, et al. Breakthrough infections after COVID-19 vaccination: insights, perspectives and challenges. Metabol Open. 2022;14:100180. doi:10.1016/j.metop.2022.100180
Accessed on 9th August 2022. https://apps.who.int/iris/handle/10665/338882
Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med. 2021;385(6):562-566. doi: 10.1056/NEJMsb2104756
Chia PY, Xiang Ong SW, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. Clin Microbiol Infect. 2022;28(4):612.e1-612.e7. doi:10.1016/j.cmi.2021.11.010
Cobey S, Larremore DB, Grad YH, Lipsitch M. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol. 2021;21:330-335.
Kaplan RM, Milstein A. Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci USA. 2021;118(10):e2021726118. doi:10.1073/pnas.2021726118
Norhayati MN, Che Yusof R, Azman YM. Systematic review and meta-analysis of COVID-19 vaccination acceptance. Front Med. 2022;8:783982. doi:10.3389/fmed.2021.783982
Baden LR, El Sahly HM, Essink B, et al, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(11):1615-1617. doi:10.1093/cid/cis238
Bridges JP, Vladar EK, Huang H, Mason RJ. Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Thorax. 2022;77(2):203-209. doi:10.1136/thoraxjnl-2021-217561
Ramasamy R. Innate and adaptive immune responses in the upper respiratory tract and the infectivity of SARS-CoV-2. Viruses. 2022;14:933. doi:10.3390/v14050933
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-407. doi:10.1016/j.healun.2020.03.012
Corbett KS, Nason MC, Flach B, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373(6561):eabj0299. doi:10.1126/science.abj0299
Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1553-1559. 10.15585/mmwr.mm7044e3
Qin CX, Moore LW, Anjan S, et al. Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients. Transplantation. 2021;105(11):e265-e266. doi:10.1097/TP.0000000000003907
Massie AB, Werbel WA, Avery RK, Po-Yu Chiang T, Snyder JJ, Segev DL. Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era. Am J Transplant. 2022;22(8):2077-2082. doi:10.1111/ajt.17036
Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study. Clin Infect Dis. 2022;75(1):e630-e644. doi:10.1093/cid/ciac103
Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney outcomes in long COVID. J Am Soc Nephrol. 2021;32(11):2851-2862. doi:10.1681/ASN.2021060734